[1]
|
New spiro-indeno[1,2-
b
]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights
Journal of Enzyme Inhibition and Medicinal Chemistry,
2023
DOI:10.1080/14756366.2023.2281260
|
|
|
[2]
|
Synthesis of Some Novel Benzimidazole Derivatives as Anticancer Agent
and Evaluation for CDK2 Inhibition Activity
Medicinal Chemistry,
2022
DOI:10.2174/1573406417666210304100830
|
|
|
[3]
|
Some illuminating remarks on molecular genetics and genomics as well as drug development
Molecular Genetics and Genomics,
2020
DOI:10.1007/s00438-019-01634-z
|
|
|
[4]
|
Metabolic stability and its role in the discovery of new chemical entities
Acta Pharmaceutica,
2019
DOI:10.2478/acph-2019-0024
|
|
|
[5]
|
Metabolic stability and its role in the discovery of new chemical entities
Acta Pharmaceutica,
2019
DOI:10.2478/acph-2019-0024
|
|
|
[6]
|
Metabolic stability and its role in the discovery of new chemical entities
Acta Pharmaceutica,
2019
DOI:10.2478/acph-2019-0024
|
|
|
[7]
|
Metabolic stability and its role in the discovery of new chemical entities
Acta Pharmaceutica,
2019
DOI:10.2478/acph-2019-0024
|
|
|
[8]
|
Biotransformation of 4‐fluoro‐N‐(1‐{2‐[(propan‐2‐yl)phenoxy]ethyl}‐8‐azabicyclo[3.2.1]octan‐3‐yl)‐benzenesulfonamide, a novel potent 5‐HT7 receptor antagonist with antidepressant‐like and anxiolytic properties: In vitro and in silico approach
Journal of Biochemical and Molecular Toxicology,
2018
DOI:10.1002/jbt.22048
|
|
|
[9]
|
Biotransformation of 4-fluoro-N
-(1-{2-[(propan-2-yl)phenoxy]ethyl}-8-azabicyclo[3.2.1]octan-3-yl)-benzenesulfonamide, a novel potent 5-HT7
receptor antagonist with antidepressant-like and anxiolytic properties: In vitro and in silico approach
Journal of Biochemical and Molecular Toxicology,
2018
DOI:10.1002/jbt.22048
|
|
|
[10]
|
Targeting cell cycle regulation in cancer therapy
Pharmacology & Therapeutics,
2013
DOI:10.1016/j.pharmthera.2013.01.011
|
|
|